| Original language | English (US) |
|---|---|
| Pages (from-to) | 690-693 |
| Number of pages | 4 |
| Journal | Thrombosis and Haemostasis |
| Volume | 121 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2021 |
All Science Journal Classification (ASJC) codes
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Thrombosis and Haemostasis, Vol. 121, No. 5, 01.05.2021, p. 690-693.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters
AU - Reshef, Avner
AU - Levy, Donald
AU - Longhurst, Hilary
AU - Cicardi, Marco
AU - Craig, Timothy
AU - Keith, Paul K.
AU - Feussner, Annette
AU - Feuersenger, Henrike
AU - Machnig, Thomas
AU - Prusty, Subhransu
AU - Pragst, Ingo
N1 - Funding Information: This work was funded by CSL Behring. Medical writing and editorial support were provided by Luis Araujo and Bhawna Basin of Trilogy Writing & Consulting GmbH. Funding Information: A.R. has received research grant support to institution from CSL Behring, Shire HGT, Pharming, Stallergenes, BioCryst, and Teva. D.L. is a researcher, speaker, and consultant to CSL Behring, speaker to Takeda, and consultant to BioCryst. H.L. has received grant support, personal fees, and nonfinancial support from CSL Behring during the conduct of the trial, grant support from BioCryst and Takeda, personal fees from Adverum, BioCryst, Pharming, and Takeda, travel support from CSL Behring, and nonfinancial support from Pharming and Takeda. M.C. received grants from Shire and personal fees from Alnylam, Bio-Cryst Pharmaceuticals, CSL Behring, Dyax, KalVista, Pharming Technologies, Shire, Sobi (Swedish Orphan Bio-vitrum), and ViroPharma. T.C. reports grant support from CSL Behring during the conduct of the trial. He is a speaker to CSL Behring, Takeda, and Grifols, a consultant to CSL Behring, Takeda, and BioCryst. He has received research support from CSL Behring, Takeda, and BioCryst. P.K.K. reports grant support from AstraZeneca, CSL Behring, Genentech, and Shire. All other authors declare no competing interests.
PY - 2021/5/1
Y1 - 2021/5/1
UR - http://www.scopus.com/inward/record.url?scp=85096673638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096673638&partnerID=8YFLogxK
U2 - 10.1055/s-0040-1721147
DO - 10.1055/s-0040-1721147
M3 - Letter
C2 - 33202446
AN - SCOPUS:85096673638
SN - 0340-6245
VL - 121
SP - 690
EP - 693
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 5
ER -